Breaking Headlines

Category archive

medicine

Medical Ceramics Market is Expected to Reach $5,841 Million by 2022, Globally-Allied Market Research

in BREAKING NEWS/Business and Finance/Health/medical ceramics/medicine/organizations/Press Release by
Reading Time: 3 minutes

PORTLAND, Oregon and PUNE, India, March 15, 2017 /360WiseNews/ —

A new report published by Allied Market Research titled, Medical Ceramics Global Opportunity Analysis and Industry Forecast, 20142022“, projects that the global medical ceramics market was valued at $3,850 million in 2015, and is expected to reach $5,841 million by 2022, registering a CAGR of 6.2% from 2016 to 2022. Implants segment is expected to remain the highest revenue contributor throughout the forecast period. U.S. held the leading position in the global market in 2015, and is expected to maintain its lead throughout the study period.

 

Summary of the Medical Ceramics Market can be accessed on the website at:https://www.alliedmarketresearch.com/medical-ceramics-market

According to Eswara Prasad, Team Lead Chemical Research at Allied Market Research, Medical ceramics are widely preferred in dentistry due to their large compressive and load bearing capacity and similarity with dental materials such as enamel.

The upsurge in the demand for medical ceramics from medical device industry creates attractive opportunities for market growth. Properties of medical ceramics such as high compressive strength and biodegradability, which are necessary for bone implants are leading market growth. Medical ceramics minimize bone ingrowth, which is a key factor boosting its adoption in the market. Growth in applications of medical ceramics for inartificial total hip, knee, shoulder, elbow, wrist; bone plates, screws, wires; intramedullary nails; permanently implanted artificial limbs; spinal fusion; alveolar bone replacements, mandibular reconstruction; and tooth replacement implants has opened new growth avenues for medical ceramics market. Growth in ceramic implants market has also fueled the demand for medical ceramics as it can be framed to match the material properties of a natural bone.

The application of the medical ceramics in the implants segments holds highest share in 2015 and is expected to maintain its lead throughout the forecast period. The increase in use of ceramics as rigid materials to manufacture implants is due to absence of prosthetics, thus reducing the risk of bacterial growth. Zirconia and alumina are the most commonly used ceramic materials used to develop implants. Zirconia, a type of bio-inert ceramic is expected to be the fastest growing segment in the global medical ceramics market followed by piezo ceramics. Ceramics are preferred for orthopedic implants by manufacturers due to their high resistance and biochemical inertness. Alumina is the most commonly used ceramic utilized for manufacturing orthopedic implants. Keep Reading

New Collaboration Improves Access to Treatment for Familial Hypercholesterolemia (FH) Patients Most at Risk for Early Heart Attacks and Death

in advocacy/brands/BREAKING NEWS/Business and Finance/medicine/non profit/organizations/Partnership/pharmacy/Press Release by
Reading Time: 2 minutes

In collaboration with The FH Foundation, Express Scripts expands access to PCSK9 inhibitors for those with FH.

PASADENA, Calif., March 15, 2017 /360WiseNews/ — The FH Foundation, a patient-centered non-profit dedicated to research, advocacy, and education of all forms of familial hypercholesterolemia (FH), today announced its collaboration with Express Scripts, a leading pharmacy benefit manager, to improve pharmacy coverage for patients with FH, an inherited genetic disorder that causes high LDL-cholesterol from birth. With a more comprehensive set of diagnostic criteria, a broader group of patients will have access to cutting-edge PCSK9 inhibitor treatment, as appropriate.

“The FH Foundation applauds Express Scripts for its leadership, working with the FH Foundation to ensure that high-risk FH patients, for whom these novel therapies were approved, will have access to the care their healthcare provider has recommended,” said Katherine Wilemon, Founder and CEO of the Foundation. “Collaboration and open communication among stakeholders in the fragmented US healthcare system are vital to informing and delivering optimum care and improving health of the American public.”

More than 1.3 million Americans, or 1 in 250 people, suffer from FH, a genetic disorder that can significantly increase the risk for early heart disease and even death. Often undistinguished from other causes of high cholesterol, FH is under-diagnosed and undertreated. However, with early diagnosis and optimal treatment, the risk for heart disease can be lowered to almost that of the general population.

With these new, more inclusive criteria put into practice by Express Scripts last month, patients with an untreated LDL-cholesterol (LDL-C) equal to or greater than 190 mg/dL whose LDL-cholesterol is still over 70 mg/dL on maximally tolerated statins plus Zetia will qualify for prior authorization for a prescribed PCSK9 inhibitor. Other diagnostic criteria to better define the condition of FH were also added. Keep Reading

Global Atopic Dermatitis Drugs Market 2017-2021

in BREAKING NEWS/dermatitis/disease/Health/medicine/public relations/research market by
Reading Time: 2 minutes

NEW YORK, March 7, 2017 /360WiseNews/ — Atopic Dermatitis Drugs

Atopic dermatitis is a common, chronic, relapsing, inflammatory disease that primarily affects young children. Atopy refers to an inherited tendency to produce IgE antibodies, whereas, dermatitis means inflammation of the skin. Atopic dermatitis is associated with asthma, inhalant allergies (hay fever), and chronic dermatitis. In this condition, the skin becomes extremely itchy and inflamed, which causes redness, cracking, weeping, swelling, vesicle formation, crushing, and scaling. Atopic dermatitis is very common worldwide, and its prevalence rate is increasing. The data estimates suggest that nearly 60% of the patients develop symptoms in the first year of life, and 88%-92% develop symptoms before the age of five.

Technavio’s analysts forecast the global atopic dermatitis drugs market to grow at a CAGR of 4.20% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global atopic dermatitis drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of atopic dermatitis drugs.

The market is divided into the following segments based on geography:
– Americas
– APAC
– EMEA

Technavio’s report, Global Atopic Dermatitis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Keep Reading

North Dallas Research Associates and Cardiac Center of Texas Begin Enrollment in TOBA II BTK Clinical Trial for New Peripheral Revascularization Treatment Option

in BREAKING NEWS/cardiac/Health/knee tack/medicine/Today In History by
Reading Time: 3 minutes

Dr. Khan Deployed the First Below the Knee Tack System in the South East Region and Only Second in the Country

MCKINNEY, Texas, March 2, 2017 /360WiseNews/ — North Dallas Research Associates and its private practice, Cardiac Center of Texas, announced today their participation in the Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK) clinical trial. TOBA II BTK is a study that offers physicians a new option to treat patients suffering from advanced peripheral artery disease (PAD) or critical limb ischemia (CLI). Using the Tack Endovascular System®, the innovative technology is designed specifically to repair dissections following standard balloon angioplasty in the popliteal and tibial arteries with minimal stress to the vessels.

“We’re very excited to enroll the first patient in Texas to be treated in this groundbreaking clinical study,” said Dr. M. Akram Khan, Cardiologist at Cardiac Center of Texas. “TOBA II BTK provides the latest vascular technology for those in the Dallas area suffering from advanced PAD.”

PAD is a disease of the blood vessels in the legs and feet that occurs when arteries become narrow or clogged and don’t receive enough blood flow to meet the body’s needs. A recent analysis suggests more than 8 million Americans have peripheral artery disease, with 12-20% of individuals ages 65+ being affected. When left untreated, PAD can lead to critical limb ischemia (CLI), a more serious form of the disease. There are more than one million people in the United States living with CLI. CLI patients experience similar symptoms to PAD patients; however, CLI symptoms can significantly increase in severity from pain when resting, to open sores, to life-threatening conditions like gangrene, and can eventually require limb amputation in some patients. According to the U.S. Department of Health and Human Services, clogged arteries in the legs, just like clogged arteries in the heart, put individuals at risk for heart attack or stroke.

The Tack Endovascular System is equipped with self-sizing technology that allows one Tack implant to fit arteries ranging from 1.5mm to 4.5mm in diameter. This flexibility eliminates the need to precisely size the device to the arterial diameter, which is necessary with conventional stents. The device then allows physicians to “spot treat” the vessel only where dissections are present, rather than leave dissections untreated or covering them with large metal stents. This technique minimizes the amount of implanted metal and reduces vessel trauma and inflammation.

“Advanced PAD and CLI are large areas of fast-growing unmet need, both clinically and from a health economics perspective,” added Dr. Khan. “Patients with CLI suffer from debilitating symptoms and have few effective treatment options. It is important for the medical community to collaborate in this study to further the treatment options for patients with such advanced disease.”

Additional information regarding this trial can be found at clinicaltrials.gov by searching the term NCT02522884.

About the Tack Endovascular System and the TOBA II BTK Clinical Trial
For more information about the TOBA II BTK trial, please visit www.intactvascular.com

About North Dallas Research Associates and Cardiac Center of Texas
Established in 2003 by Dr. M. Akram Khan, NDRA has grown steadily for more than 10 years building expertise in clinical research operations. We are a team of professional and dedicated staff led by Dr. Khan, who manages and conducts a vast variety of clinical trials. Currently, the site has three principal investigators conducting clinical trials under various specialties. Keep Reading

Animal Dermatology Clinic Pasadena is home to a new treatment that could signal relief for pets

in Animals/BREAKING NEWS/Health/medicine/pets by
Reading Time: 2 minutes

PASADENA, Calif., March 2, 2017 /360WiseNews/ — Animal Dermatology Clinic (ADC) Pasadena is now offering a new treatment that speeds up the healing process for pets, with Hyperbaric Oxygen Therapy (HBOT). Introduced in human medicine as the primary treatment for decompression sickness after diving, hyperbaric oxygen therapy delivers a high oxygen concentration, combined with increased air pressure in the chamber, allowing oxygen to diffuse into the tissues to advance the healing process.

ADC Pasadena remains on the forefront of innovating its practice by currently being the only dermatology specialist in the world to offer this state-of-the-art equipment in-house. This new technology enhances ADC’s years of experience and advancements in clinical research which will further its impact on the future of veterinary dermatology. These contributions to the veterinary community will continue to demonstrate ADC’s commitment to excellence in patient care.

The use of hyperbaric oxygen therapy in veterinary medicine has been used to heal a variety of medical conditions through a noninvasive treatment that delivers 100-percent oxygen under pressure. It has been very effective for non-healing wounds, burns, deep tissue infections, bone infections, decubital ulcers, vasculitis, and post-surgical recovery. Keep Reading

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of UnitedHealth Group Incorporated (UNH)

in BREAKING NEWS/Business and Finance/Health/medicine by
Reading Time: 1 minute

NEW YORK, Feb. 20, 2017 /360WiseNews/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of UnitedHealth Group Incorporated (“UnitedHealth” or the “Company”) (NYSE: UNH). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/unh.

The investigation concerns whether UnitedHealth and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On February 16, 2017, a False Claims Act lawsuit against UnitedHealth was made public following the appeal of the U.S. Department of Justice. The complaint filed in 2011 under seal, alleges that UnitedHealth and other insurers had participated in a scheme to overcharge Medicare by “hundreds of millions — and likely billions — of dollars” for over a decade.  Following this news, UnitedHealth stock dropped $6.03 per share, or 3.68%, to close at $157.62 on February 17, 2017.

If you are aware of any facts relating to this investigation, or purchased shares of UnitedHealth, you can assist this investigation by visiting the firm’s site: www.bgandg.com/unh. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.  Keep Reading

Entrepreneur Not ‘Eclipsed’ by Diagnosis

in BREAKING NEWS/Business and Finance/Entertainment/Health/medicine by
Reading Time: 2 minutes

MEMPHIS, Tenn., Feb. 20, 2017 /360WiseNews/ — There’s no good time to learn that your new reality consists of one of the scariest words known to man – cancer. But John Jerit received this news at what he now considers to have been the worst time. Less than two years out from an event that he has literally been waiting for his entire life, John was shocked to hear that his annual prostate screening uncovered cancerous cells.

As of December 2015, life for John would never be the same.

But, this life-altering moment didn’t create the kind of bone-chilling fear one would assume hits when you learn of your own cancer diagnosis. In fact, John admits he was only moderately concerned about how the cancer would affect his health, family and finances. On the contrary, when he learned that cancer was now part of his life story, John’s thoughts turned to Aug. 21, 2017. This date marks the first time since 1979 that the U.S. will experience a total solar eclipse…and John planned to live to witness it, one way or another.

As owner and CEO of American Paper Optics, the largest manufacturer of 3D and safe solar eclipse glasses in the world, John’s career dream has been to personally view and make sure that every American is afforded the opportunity to safely view this eclipse. In February 2016, John’s dream slowly morphed into a strong possibility as he successfully underwent robotic surgery. Then, as he started down his road to recovery, John became more and more inspired to get eclipse glasses in the hands of as many people as possible.

John wanted people across the country to understand that no matter where they are geographically located on Aug. 21, they’ll need to wear the CE and ISO-certified glasses that APO makes to safely view the eclipse. The glasses, which are close to 1,000 times darker than regular sunglasses, are THE safest way to view the solar eclipse because they filter out 100% of harmful ultra-violet and infrared rays and 99.999% of intense visible light. Additionally, the glasses can be custom branded to fit any company’s design preferences. Keep Reading

Caprion Biosciences to Lead Short Course and Present Poster at Molecular Medicine Tri-Conference in San Francisco

in Business and Finance/Health/medicine by
Reading Time: 2 minutes

Short Course to Highlight Intracellular Cytokine Detection Assay in Adoptive Cell 

Therapy Trials and Poster to Highlight Metaproteomic Analysis of Gut Microbiome in
Enfants

MONTREAL, Feb. 17, 2017 /360WiseNews/ – Caprion Biosciences Inc. announced today that Dr. Yoav Peretz, Scientific Director of ImmuneCarta will lead a short course on novel techniques in development of Intracellular cytokine detection assays in adoptive cell therapy trials at the annual Molecular Medicine Triconference held in San Francisco, CA.  The course will focus on providing guidance on detection, persistence, and phenotypic characterization of pentamer CD8+ T cells in adoptive cell immunotherapy trials.

Caprion will also have a poster presentation which features an exploratory discovery study on metaproteomic analysis of infant fecal microbiome.  The goal of the study was to extract gut microbiome taxonomy and functional data in a population of infant fecal samples. The results demonstrate a proteomics approach provides functional changes and responses with significantly greater coverage of bacterial genera than the pyrosequencing approach. Pathway analysis also underlines the differences between individual microbiomes and provides insights into their functional responses to diet, disease and therapy.

Short Course: Development and Deployment of an Intracellular Cytokine Detection Assay in Adoptive Cell Therapy Trials
SC24 “Flow Cytometry and Phenotypic Cell Analysis in Immuno-Oncology”
Speaker: Yoav Peretz, PhD, Scientific Director, ImmuneCarta
Monday, Feb 20th, 10:10am

Poster presentation at the conference
“Metaproteomic Analysis of the Infant Fecal Microbiome”
Laetitia Cortes1, Aude Tartière1, Julie Piquenot1, Sebastian Tims2, Joost W. Gouw2, Jan Knol2,3, Harm Wopereis2,3 and Daniel Chelsky1 1Caprion Biosciences Inc, Montreal, Canada; 2Nutricia Research, Utrecht, the Netherlands; 3Wageningen University, Laboratory of Microbiology, Wageningen, the Netherlands Keep Reading

Go to Top